Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 6/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.43 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.43 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733775 | 0.76 | HIF1A (0.57) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6733742 | 0.73 | ALDH1A1 (0.56) | CDK5CDK5R1KDM4EMEN1KMT2A | |
| SCHEMBL6737254 | 0.73 | CYP2D6 (0.44) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6734315 | 0.73 | HRH3 (0.54) | CDK5CDK5R1KDM4EALDH1A1 | |
| SCHEMBL6736754 | 0.71 | ACKR3 (0.41) | CDK5CDK5R1KDM4EMEN1KMT2A | |
| SCHEMBL6736756 | 0.70 | CDK5 (0.48) | CDK5CDK5R1KDM4EMEN1KMT2A | |
| SCHEMBL206621 | 0.69 | MEN1 (0.48) | KDM4EMEN1KMT2AWNK1 | |
| SCHEMBL29280456 | 0.69 | KDM4E (0.72) | KDM4EMEN1KMT2AUSP2ALDH1A1 | |
| SCHEMBL12563565 | 0.69 | CYP2D6 (0.69) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6215918 | 0.68 | HIF1A (0.52) | ACP1KDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087063-A1 | IMIDAZOLIDINE COMPOUNDS AS CHEMOKINE RECEPTOR MODULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | ACP1 1611/4885HTR4 3499/4885CDK5 2189/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | ACP1 1611/4885HTR4 3499/4885CDK5 2189/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | ACP1 1611/4885HTR4 3499/4885CDK5 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.